| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Tourmaline Bio, Inc.$47.98
0 (0%)
C 42Pipeline Score Fair Value Biotech · Clinical
Market Cap
1.23 B
EPS
-3.44
P/E Ratio
-
Value Trade
37.61 M
0.17 %
Week
0.52 %
1 Month
111.27 %
3 Month
201.38 %
6 Month
-72.19 %
5 Year
-72.19 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
783.73 K
52 Week Range
11.56 - 48.27
% held by Insiders
36.27 %
% held by Institutions
72.7 %
Enterprise Value
993.63 M
Total Shares
25.69 M
Short %
5.51 %
Float Shares
14.68 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C42
Pipeline Score $1.2B
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.0x
rNPV / MCap Top 62%
Micro Cap (rank 345 of 905)
Percentile RankTourmaline Bio, Inc. carries a moderate pipeline score (42/100), with $3.7B risk-adjusted pipeline value, led by TOUR006 - in Chronic Kidney Diseases (Phase 2), across $103B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOUR006 - Small molecule | Chronic Kidney Diseases | Phase 2 | NCT06362759 | 16% | $3.2B | COMPLETED | 143 | - | - | Dec 4, 2025 | - | Feb 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
pacibekitug | atherosclerotic cardiovascular disease,chronic kidney disease | Phase 2 | 2025-08-13 | |||
pacibekitug | atherosclerotic cardiovascular disease,chronic kidney disease | Phase 2 | 2025-08-13 | |||
pacibekitug | atherosclerotic cardiovascular disease,chronic kidney disease | Phase 2 | 2025-08-13 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TRML
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Tourmaline Bio, Inc. (TRML) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
TRML
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TRML
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TRML
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TRML Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
TRML Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How TRML ranks across every disease it competes inCompetitive Position is a premium feature
See how TRML ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial